<DOC>
	<DOCNO>NCT01534182</DOCNO>
	<brief_summary>A 6-month , Randomized , Active Comparator , Open-label , Multi-Center Study Evaluate Patient Outcomes , Safety Tolerability ( fingolimod ) 0.5 mg/day Patients Relapsing Remitting Multiple Sclerosis candidate MS therapy change Previous Disease Modifying Therapy .</brief_summary>
	<brief_title>Evaluation Patient Reported Outcomes RRMS Patients Candidates MS Therapy Change Transitioned Fingolimod 0.5 mg ( EPOC )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Patients must diagnose relapse remit MS ( RRMS ) define 2005 revise McDonald criterion ( McDonald et al 2001 , Polman et al 2005 ) ( Appendix 2 ) . Patients explicitly agree assigned treatment group may receive DMT inform respective benefit possible adverse event investigator . Male female patient age 1870 year . An Expanded Disability Status Scale ( EDSS ) score 06 inclusive . Must receive continuous treatment single approve indicated MS DMT minimum 6 month prior screen visit . Patients must continue MS DMT randomization visit . Na√Øve treatment fingolimod . A manifestation MS define inclusion criterion . A history chronic disease immune system MS know immunodeficiency syndrome . History malignancy organ system . Diagnosis macular edema Screening Phase . Patients active systemic bacterial , viral fungal infection , know AIDS positive HIV antibody test . Patients receive live live attenuate vaccine ( include varicellazoster virus measles ) within 2 month prior baseline . Patients receive total lymphoid irradiation bone marrow transplantation . History select immune system treatment and/or medication . Any medically unstable condition , assess investigator . Selected cardiovascular , hepatic condition Selected abnormal laboratory value . Patients disease clinical condition ( include neurologic psychiatric disorder ) may affect patient enrollment study study medication use Investigators ' opinion . Participation clinical research study evaluate another approve Russia investigational drug therapy within 6 month prior baseline . History hypersensitivity study drug drug similar chemical class . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis ( RRMS )</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Disease Modifying Therapy ( DMT )</keyword>
	<keyword>TSQM-9</keyword>
</DOC>